Clinical Trial Update: Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 efficacy study of TLN-232 in patients with recurring metastatic melanoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• TLN-232

Snippet

Sponsor: Thallion Pharmaceuticals | Conditions: Melanoma | Phase 2 | Status: TERMINATED